The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This article was retracted on November 1, 2006

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow A retraction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rakoff-Nahoum, S.
Right arrow Articles by Sperber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rakoff-Nahoum, S.
Right arrow Articles by Sperber, K.
The Journal of Immunology, 2001, 167: 2331-2342.
Copyright © 2001 by The American Association of Immunologists

Regulation of Class II Expression in Monocytic Cells after HIV-1 Infection1

Seth Rakoff-Nahoum, Houchu Chen, Thomas Kraus, Italas George, Erwin Oei, Max Tyorkin, Erez Salik, Prarthana Beuria and Kirk Sperber2

Division of Clinical Immunology, Mount Sinai School of Medicine, New York, NY 10029


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Human macrophage hybridoma cells were used to study HLA-DR expression after HIV-1 infection. HLA-DR surface expression was lost 2 wk after infection that was associated with decreased mRNA transcription. Transfecting HLA-DR-{alpha} and HLA-DR-{beta} cDNA driven by a nonphysiological CMV promoter restored expression, suggesting that regulatory DNA-binding proteins may be affected by HIV-1 infection. There was no protein binding to conserved class II DNA elements (W/Z/S box, X-1 and X-2 boxes, and Y box) in a HIV-1-infected human macrophage hybridoma cell line, 43HIV, and in primary monocytes that lost HLA-DR expression after HIV-1BaL infection. PCR analysis of the HIV-1-infected cells that lost HLA-DR expression revealed mRNA for W/Z/S (RFX-5), X-1 (RFX-5), X-2 (hX-2BP), and one Y box DNA-binding protein (NF-YB), and CIITA, a non-DNA-binding protein necessary for class II transcription. There was no mRNA for the Y box-binding protein, NF-YA. However, HLA-DR expression could be restored by transfection with NF-YA driven by a CMV promoter, although HLA-DR failed to localize in either the late endosomes, lysosomes, or acidic compartments. This was associated with a loss of class II-associated invariant chain peptide and leupeptin-induced protein in the 43HIV cells. To address this further, non-HIV-1-infected 43 cells were infected with vaccinia virus containing HIV-1 gag, nef, pol, and env proteins. HLA-DR failed to localize in neither the late endosomes, lysosomes, or acidic compartments in the vaccinia-infected cells containing HIV-1 env protein. HIV-1 appears to have multiple effects on class II expression in monocytic cells that may contribute to the immune defects seen in HIV-1-infected patients.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Macrophages play a critical role in immune regulation through Ag processing that is critical for T cell recognition of Ag (1). Macrophages process and present Ag through a multistage pathway that involves the breakdown of proteins into immunogenic peptides that complex with class II molecules, expression of costimulatory molecules, and production of accessory cytokines (2). Macrophages also have an important role in HIV-1 infection, serving not only as a reservoir for virus, but also contributing to the immune defects seen in HIV-1-infected patients (3, 4, 5, 6, 7, 8). A number of monocyte defects have been reported during different stages of HIV-1 infection, including impaired class II Ag expression, chemotactic defects, and aberrant cytokine production (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19). Progressive impairment of monocytic function may contribute to the overall immune dysregulation that is observed in HIV-1-infected patients (20). The study of monocytic function after HIV-1 infection has been hampered by the lack of in vitro model systems. Our laboratory has generated a panel of human macrophage hybridoma cell lines that possess many normal monocytic functions and can be uniformly infected by HIV-1 (21, 22, 23, 24, 25). Using this system, we have demonstrated an impaired ability of HIV-1-infected hybridomas to present soluble Ag to MHC-matched responder T cells, which was associated with the loss of HLA-DR mRNA expression (22, 25). The block in mRNA expression could be overcome by transfection with HLA-DR-{alpha} and HLA-DR-{beta} genes driven by a CMV promoter gene, suggesting that HIV-1 was mediating this effect by altering the regulation of mRNA production (25). Recently, this finding has been confirmed by other investigators (26).

Constitutive and induced class II expression in APC is regulated by a series of DNA-binding proteins that bind to conserved regulatory elements (W/S/Z, X-1, X-2, and Y boxes) and the class II MHC transactivator (CIITA),3 a non-DNA-binding protein transcription factor (27, 28, 29, 30, 31). In the present study, we first investigated whether HIV-1 infection interfered with DNA binding to the W/S/Z, X-1, X-2, Y box elements, or whether there was a direct effect on CIITA. We also determined whether the production of DNA-binding proteins RFX-5-W/Z/S and X-1, hX-2BP-X-2, NF-YA, and NF-YB-Y box) was suppressed after HIV-1 infection. In our previous studies, even though HLA-DR expression was restored after transfection with HLA-DR, the HIV-1-infected human macrophage hybridomas were incapable of inducing Ag-specific T cell proliferation (22, 25). In this study, we investigate whether there may be either a loss of invariant chain (Ii) production that chaperones HLA-DR into different subcellular compartments, an effect on HLA-DM-{alpha} and HLA-DM-{beta}, nonpolymorphic MHC gene products necessary for Ag processing, or impaired sorting of HLA-DR into subcellular compartments.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Human macrophage hybridomas

Human macrophage hybridomas were obtained by fusing macrophages (obtained by allowing monocytes to mature into macrophages in Teflon bag cultures) with a hypoxanthine-guanine phosphoribosyltransferase-deficient promonocytic line (U937), as previously described (21). We have uniformly infected and characterized one clone, 43, with different strains of HIV-1 (43HIV) (25).

Monocyte isolation

Mononuclear cells were separated from buffy coats obtained from normal healthy volunteers by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density gradient centrifugation. The cells were washed three times with sterile PBS and resuspended in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS (Life Technologies), 2 mM L-glutamine, and 1% penicillin/streptomycin (Life Technologies), henceforth called complete medium (CM). Freshly isolated PBMCs were incubated at 37°C in CM and allowed to adhere for 45 min. The nonadherent cells were removed, and adherent cells were washed with sterile PBS, harvested with a rubber policeman, and stained with monocyte-specific anti-CD14 mAbs to assess the purity of the preparation. Ninety percent of the isolated cells expressed CD14 (21).

HIV-1 infection

Monocytes or clone 43 cells were infected with HIV-1ADA, HIV-187.9, HIV-1BaL, and HIV-1IIIB, respectively, as previously described (25). These reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (Bethesda, MD). Dilutions of HIV-1-containing supernatant standardized to contain reverse-transcriptase activity (80,000 cpm/ml) were incubated for 90 min, followed by three washes with PBS.

DNA-binding studies

Oligonucleotides were synthesized for the W/Z/S, X-1, X-2, and Y box-binding studies by Integrated DNA Technologies (Coralville, IA) and labeled with 32P dCTP, dATP, dGTP, and dTTP (ICN Pharmaceuticals, Irvine, CA) using DNA polymerase I (Sigma, St. Louis, MO) (32). Nuclear protein was extracted from 43 and 43HIV, and monocytes were infected with HIV-1BaL that retained (HLA-DR+) and lost (HLA-DR-) HLA-DR expression, according to the protocol of Dingham (33). Ten million cells were resuspended in 100 mM pepstatin A (Sigma), 10 mg/ml leupeptin (Sigma), 100 mM PMSF (Sigma), and 10 mg/ml aprotinin (Sigma). The cells were lysed with 20 mM HEPES (Sigma), pH 7.9, 1.5 mM MgCl2 (Sigma), 10 mM KCl (Sigma), and 1 mM DDT (Sigma), and then centrifuged at 10,000 rpm for 30 s. The nuclei containing supernatant were added to 20 mM HEPES (Sigma), pH 7.9, 1.5 mM MgCl2 (Sigma), 0.2 mM EDTA (Sigma), 20% glycerol (Sigma), 0.42 mM KCl (Sigma), and 1 mM DTT (Sigma); incubated on ice for 30 min; and then centrifuged for 5 min at 15,000 rpm. The nuclei were then added to the DNA oligonucleotides in Murphy’s binding buffer (BD PharMingen, San Diego, CA) for 2 h at room temperature. After binding, the mixture was electrophoresed on a 10% polyacrylamide gel, which was exposed to x-ray films (Kodak, Renseassler, NY) overnight and developed. In some experiments, the specificity of the binding was determined by adding 10 µg unlabeled oligonucleotide probes.

Surface and intracytoplasmic immunofluorescence

The HIV-1BaL-infected monocytes, 43, and 43HIV cells were stained by indirect methods, as previously described, with various mAbs (see below) or with isotype-matched controls, followed by affinity-purified F(ab')2 FITC-conjugated goat anti-mouse Ig Ab (Tago Scientific, Burlingame, CA), and analyzed by flow cytometry gating on live cells (21). The anti-class I Abs (W6/32) were obtained from the American Type Culture Collection (ATCC; Manassas, VA); anti-DR Abs, anti-class II-associated Ii peptide (CLIP), anti-CD80, and anti-CD86 Abs were purchased from BD Biosciences (Mountain View, CA); and the human polyclonal anti-HIV-1 Abs were a kind gift of A. Pinter (New York University, New York, NY). For intracytoplasmic staining, cells were fixed and permeabilized with 70% ethanol for 30 min at 4°C. The cells were then washed three times with PBS, and polyclonal anti-HIV-1 Abs or noninfected control Abs were added for 30 min at 4°C, followed by affinity-purified FITC-conjugated goat anti-human Ig Ab (Tago Scientific), and analyzed as described above (25).

RT-PCR for CIITA, RFX-5, hX-2BP, NF-YA, NF-YB, Ii, HLA-DM{alpha}, HLA-DR{beta}, and actin

Sequences for oligonucleotide primers used for PCR amplification and the size of the predicted PCR products are as follows: CIITA predicted size PCR product, 5'-CAACTCCCTGAAGGATGTGGA-3', 350 bp, and 5'-ACGTCCATCACCCGGAGGGAC-3'; RFX-5, 5'-CGAGAATTCAGCTGTATCTCTACCTTC-3', 586 bp, and 5'-GTCGAATTCAGGGAAGATCTCTCTGATG-3'; hX-2BP, 5'-ACCCCTAAAGTTCTGCTTCTGTCG-3', 738 bp, and 5'-CATTAATGGCTTCCAGCTTGGCTG-3'; NF-YA,5'-GCAATAGTTCCACAGAGCAGATCG-3', 929 bp, and 5'-CTAGGGATTTCTGCAGACTACATCGG-3'; NF-YB, 5'-ACTCGGATGATCTGTGTTCATGGCT-3', 490 bp, and 5'-AGCCAGCTGGTAACTGGTTAGTGA-3'; Ii, 5'-TCCCAAGCCTGTGAGCAAGATG-3', 410 bp, and 5'-CCAGTTCCAGTGACTCTTTCG-3'; HLA-DM-{alpha}, 5'-ACTTTTCCCAGAACACTCGG-3', 341 bp, and 5'-CTGGAAGCTGAGTCCATC-3'; HLA-DM-{beta}, 5'-ACAGCCACCTCAACCAAAAAGA-3', 321 bp, and 5'-GGGGTTAAGGCTAAATGGGA-3'; and actin, 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3', 661 bp, and 5'-CTAGAAGCATTGCGGTGGACGATGGAGGG-3'.

These primer sets have been previously published (27) and were synthesized by Integrated DNA Technologies. RNA was extracted from 43 and 43HIV, HLA-DR+, and HLA-DR- HIV-1BaL-infected monocytes using acid guanidium thiocynate/phenol/chloroform, as described previously (RNAzol, Linnai, Dallas, TX) (34). Known quantities of RNA were mixed with 1 µg total cellular RNA and reverse transcribed at 37°C for 60 min in 20 µl buffer containing 10 mM Tris (Sigma) (pH 8.3); 50 mM KCl (Sigma); 5 mM MgCl2 (Sigma); 1 mM each of dATP, dCTP, dGTP, and dTTP (Sigma); 20 U RNase inhibitor (Promega, Milwaukee, WI); 0.1 µg oligo(dT)15 (Boehringer Mannheim, Indianapolis, IN); and 50 U murine leukemia virus reverse transcriptase (Bethesda Research Laboratories, Bethesda, MD). The PCR for RFX-5, hX-2BP, NF-YA, NF-YB, HLA-DM-{alpha}, HLA-DM-{beta}, Ii, and actin was performed for 40 cycles at 94°C for 1 min, at 50°C for 1 min, and at 68°C for 3 min, with a 20-s elongation step per cycle (27). The amplification cycles were performed in the same tube for all of the X and Y box-binding proteins and for HLA-DM-{alpha}, HLA-DM-{beta}, and actin. Reactions were stopped by heat inactivation for 10 min at 95°C, annealed for 2.5 min, and extended at 65°C. Negative controls were performed omitting RNA from the cDNA synthesis and specific amplification. PCR products were separated in a 2% NuSieve agarose (FMC, Rockland, ME) or a 5% polyacrylamide gel (23).

Transfection with NF-YA

The 43HIV cells were transiently transfected with a bacterial plasmid containing NF-YA obtained through the ATCC using a DEAE-dextran method (35). The bacteria containing the NF-YA plasmid was cultured, ethanol precipitated, extracted, and then centrifuged and resuspended in TBS. The resuspended DNA was added to 10 mg/ml DEAE-dextran and incubated with the 43HIV and 63HIV cells for 4 h at 37°C. After aspirating the DEAE-dextran, the cells were shocked by adding 5 ml 10% DMSO (Sigma) in PBS for 1 min at room temperature, washed with sterile PBS, and resuspended in CM for 48 h at 37°C. In some experiments, the 43HIV cells were treated with 10 mg/ml DEAE-dextran alone without the NF-YA DNA, while in other experiments the 43HIV cells were treated with DEAE-dextran and jellyfish green fluorescent protein (Promega) to assess the efficiency of transfection.

Tetanus toxoid (TT)-induced T cell proliferation

Uninfected, HIV-1-infected (43HIV), or HIV-1-infected NF-YA-transfected 43 and 63 cells (43HIV + T) were used as accessory cells in TT-induced T cell proliferation assays. In these experiments, T cells were obtained from an HLA-matched donor (HLA-DR2+) and were monocyte depleted using a nylon wool column. The PBMC were incubated for 45 min and eluted. T cells obtained in this manner failed to proliferate to TT in the absence of accessory cells (23). Monocyte-depleted PBMC (105) were cultured with varying concentrations of 43 and 43HIV, as well as 43HIV transfected with NF-YA (103–105) and TT (0.4–40 µg/ml). The cells were maintained in 0.2 ml CM in triplicate round-bottom plates (Linbro, Oxnard, CA) at 37°C in a 5% CO2 incubator for 5 days. Eighteen hours before harvesting, 1 µCi [3H]thymidine (ICN Pharmaceuticals) was added to each well. The cells were harvested onto glass fiber filters, and incorporated radiolabel was measured by scintillation counting (23).

Annexin V

FITC-labeled annexin V, a phospholipid-binding protein of the annexin family, was used to measure apoptosis using a commercially available kit (Beckman Coulter, Hialeah, FL). After incubating 43 and 43HIV with T cells, the cell samples were washed with ice-cold PBS, followed by centrifugation at 500 x g at 4°C. The cells were stained simultaneously with annexin V FITC/PE-labeled anti-CD3 mAb and incubated at room temperature for 10 min in the dark. The cells were then analyzed by flow cytometry to measure costaining of the CD3+ and the annexin V+ population, gating on the live cells (36).

Western blot

The 43 and 43HIV cells were lysed using buffer containing PMSF (100 mM), aprotonin (10 mg/ml), leupeptin (10 mg/ml), iodoacetamide (1.8 mg/ml), and 0.1% Triton X. The lysates were resolved on a 10% SDS-PAGE gel, transferred onto a nitrocellulose membrane, blocked with 5% milk in PBS at room temperature for 60 min, then incubated with the PIN.1 mAb (37) at 4°C overnight. A secondary horseradish-labeled goat anti-mouse Ig (Tago Scientific) was then added at 25°C for 2 h, and the blot was developed by chemiluminescence using a commercially available kit (DuPont Pharmaceuticals, Wilmington, DE).

Vaccinia virus infection

Vaccinia virus-containing vectors for HIV-1 envelope, gag, pol, and nef proteins were obtained from the AIDS Research and Reference Laboratory. Vaccinia virus was added to cultures of either uninfected 43 or 63 cells at a virus to cell ratio of 108:1 that has been described previously (38). Successful infection was determined by intracytoplasmic immunofluorescence, as described above.

Colocalization studies

To colocalize HLA-DR in different subcellular compartments, we used mouse anti-cathepsin D (early endosomes) Ab (Accurate Antibodies, Westbury, NY), rabbit polyclonal anti-M6PR (late endosomes; provided by R. Dunn, University of Florida, Gainesville, FL), and mouse anti-HLA-DR (BD Biosciences). The 43 and 43HIV cells and 43 cells infected with vaccinia virus containing different HIV-1 proteins were fixed with methanol/acetic acid (3/1) for 5 min at 4°C. Fixed cells were then blocked with PBS containing 5% goat serum and 0.2% Triton X-100 (Sigma) for 45 min before incubating with the primary Ab for 1 h. The cells were rinsed with PBS three times before incubating with Texas Red-conjugated Abs directed against either rabbit or mouse Ig for 30 min. Following this incubation, the cells were again washed three times with PBS and incubated with an FITC-labeled murine anti-HLA-DR Ab. The cells were rinsed with PBS, prepared as a cytospin, and mounted with Immu-mount (Shandon, Pittsburgh, PA) before being viewed by a Leica fluorovert laser-scanning confocal microscope (Leica, Deerfield, IL) at a step position of 1 µm on the x-y-axis or x-z-axis. To localize with 3-(2,4-dinitroanilino)-3'-N-methyldipropylamine) (DAMP), the HIV-1-infected and uninfected cells were fixed with 4% paraformaldehyde in PBS for 30 min. The cells were then washed twice with 50 mM NH4Cl (Sigma) for 5 min each before permeabilization with 0.02% Triton X-100 (Sigma) in PBS for 30 min. The cells were then incubated with rabbit polyclonal rabbit anti-DAMP Abs (Molecular Probes, Eugene, OR) for 60 min at room temperature before mounting with Immu-mount (Shandon) and viewing by confocal microscopy (25).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Decreased X and Y binding in the HIV-1-infected cells

Our previous studies demonstrated a loss of HLA-DR expression in the HIV-1-infected human macrophage hybridomas that could be overcome by transfecting HLA-DR-{alpha} and HLA-DR-{beta} genes driven by a nonphysiologic CMV promoter (25). These findings suggested that HIV-1 infection had an effect on the regulation of HLA-DR mRNA production. Class II and HLA-DR mRNA production is regulated by different DNA-binding proteins that interact with a compact, conserved, multicomponent motif that contains four subelements, the W/Z/S box, the X-1 and X-2 boxes, and the Y box (39, 40, 41, 42, 43). We first investigated whether HIV-1 infection had any effect on the binding of these regulatory proteins by synthesizing oligonucleotides corresponding to the W/Z/S, X-1, X-2, and Y binding sites to use in gel-shift assays comparing HIV-1-infected with uninfected human macrophage hybridomas. We used one human macrophage hybridoma cell line (clone 43) for these experiments that lost HLA-DR expression after HIV-1 infection (22, 25). Nuclear protein extracts from 43 and 43HIV were electrophoresed on a 5% polyacrylamide gel with 32P-labeled or unlabeled oligoprobes (to assess the specificity of the DNA binding). In the 43 cells, W/Z/S, X-1, X-2, and Y box DNA binding was present and could be displaced by the unlabeled W/Z/S, X-1, X-2, and Y probes (Fig. 1GoA). However, in the 43HIV cells, there was no binding to either the W/Z/S, X-1, X-2, or Y boxes, respectively (Fig. 1GoA). Because of the conflicting reports regarding the loss of HLA-DR expression in primary monocytes after HIV-1 infection (18, 19, 22, 25), we wanted to validate our findings in the 43HIV cells using primary HIV-1BaL-infected monocytes. In freshly isolated monocytes from normal blood donors, we detected decreased surface expression of HLA-DR in 3 of 10 preparations 8 days after infection with HIV-1BaL (Table IGo). Similar results were obtained when we infected the primary monocytes with HIV-1ADA, HIV-187.9, or primary isolates from HIV-1-infected donors (data not shown). We separately pooled the nuclear extracts from the HLA-DR+ and HLA-DR- HIV-1BaL-infected monocytes and performed W/Z/S, X-1, X-2, and Y box-binding studies. Consistent with the findings in the 43HIV cells, there was reduced or absent W/Z/S, X-1, X-2, and Y box DNA binding in the HLA-DR- HIV-1BaL-infected monocytes compared with the HLA-DR+ HIV-1BaL-infected monocytes (Fig. 1GoA). CIITA is a non-DNA-binding protein and serves as a coactivation factor for class II expression (41). Lack of CIITA expression has been reported in class II-deficient patients with the bare lymphocyte syndrome (BLS) (40, 41). Competition between Tat and CIITA for binding to the P-TEBFb transcription factor has also been reported in HIV-1-infected THP-1 cells that lost class II expression (26). Although DNA binding to W/Z/S, X-1, X-2, and Y boxes can be demonstrated in CIITA-deficient patients (44), it is still possible that CIITA production may be affected by HIV-1 infection in our system and may contribute to the loss of HLA-DR expression. CIITA production was assessed by PCR in 43 and 43HIV cells and in the HLA-DR+ and HLA-DR- HIV-1BaL-infected monocytes. A 350-bp band corresponding to CIITA was detected in both the HIV-1-infected and uninfected cells (Fig. 1GoB).



View larger version (77K):
[in this window]
[in a new window]
  		FIGURE 1. DNA-binding studies in 43 and 43HIV cells and in HIV-1BaL-infected monocytes. A, Nuclear protein was extracted from HIV-1-infected (43HIV) and uninfected 43 cells, probed with 32P-labeled oligonucleotides corresponding to the W/Z/S, X-1, X-2, and Y box bindings, and run on a 10% polyacrylamide gel. Unlabeled probe was added to assess the specificity of the DNA binding (43+competitor). The gels were dried and exposed to x-ray film overnight. The arrows represent DNA binding. This is a representative experiment repeated five times. B, PCR for CIITA. RNA was extracted from 43, 43HIV, and HIVBaL-infected monocytes (HLA-DR+ and HLA-DR-). The RNA was reverse transcribed, probed with a CIITA or an actin-specific probe, and then run on a 5% agarose gel. Negative controls were performed omitting the RNA from the cDNA synthesis and amplification step. This is representative of an experiment repeated five times.

 

View this table:
[in this window]
[in a new window]
  		Table I. HLA-DR Expression in HIV-1BaL Infected Monocytes

 
Production of X and Y box-binding proteins

Because there was no DNA binding to the W/Z/S, X-1, X-2, and Y boxes, we investigated whether there was loss of the W/Z/S, X-1, X-2, or Y box-binding proteins in 43HIV, and in the HLA-DR- HIVBaL-infected monocytes. Because many DNA-binding proteins have been found to associate with class II regulatory sequences (45, 46, 47, 48, 49, 50, 51, 52, 53), we only assayed for those binding proteins that have been associated with the loss of class II expression in BLS or that cooperatively interact with other binding proteins (54). To this end, we determined the presence or absence of four DNA-binding proteins: RFX-5 (W/Z/S, X-1), hX-2BP (X-2), NF-YA, and NF-YB (Y box) by PCR in the 43HIV cells. Amplified fragments corresponding to RFX-5 (504 bp)-, hX-2BP (738 bp)-, and NF-YB (490 bp)-binding proteins could be demonstrated in the uninfected 43 and 43HIV cells (Fig. 2Go). However, a 926-bp fragment, corresponding to NF-YA, was absent in the 43HIV cells. We again wanted to validate these findings in the HLA-DR- HIVBaL-infected monocyte preparations. Fragments corresponding to RFX-5 (504 bp), hX-2BP (738 bp), and NF-YB (490 bp) DNA-binding proteins were present, but there was no detectable NF-YA (926 bp) (Fig. 2Go). Because the loss of NF-YA could potentially explain the loss of HLA-DR after HIV-1 infection in our system, we transfected the 43HIV cells with NF-YA in an attempt to restore expression.



View larger version (90K):
[in this window]
[in a new window]
  		FIGURE 2. PCR for X and Y box-binding proteins. RNA was isolated from 43 and 43HIV cells and HIVBaL-infected monocytes (HLA-DR+ and HLA-DR-), reverse transcribed, and probed with RFX-5, hX-2BP, NF-YA-A, NF-YB, and actin-specific probes, and then run on a 5% agarose gel. This is representative of an experiment repeated five times.

 
Transfection of 43HIV with the NF-YA DNA box-binding protein

We transfected full-length cDNA for the NF-YA DNA-binding protein driven by a CMV IE promoter into 43HIV cells using DEAE-dextran. The surface expression of HLA-DR was lost in the 43HIV cells 2 wk after infection, but was transiently restored after transfection with NF-YA (Fig. 3Go). Because the NF-YA-transfected 43HIV cells expressed HLA-DR, we investigated whether these were functional by assessing whether they could present TT to HLA-matched (HLA-DR2+) responder T cells. APC-depleted T cells and TT (40 µg/ml) were cocultured in the presence of varying concentrations (103-105) of either 43 and 43HIV cells or NF-YA box-transfected 43HIV cells. In the absence of accessory cells, there was no T cell proliferation in response to TT (Fig. 4Go). Uninfected 43 cells induced a TT-specific proliferative response in the HLA-DR2+ T cells, inducing increases in thymidine incorporation, whereas 43HIV failed to induce any T cell proliferation. After transfection with NF-YA, the 43HIV cells were still unable to induce T cell proliferation in response to TT (Fig. 4Go). One possible explanation is loss of CD80 and CD86 expression in the 43HIV cells. However, the surface expression of CD80 and CD86 was unchanged in the 43HIV cells compared with the uninfected 43 cells (Fig. 5Go). We have reported that after prolonged HIV-1 infection (35 days), 43HIV can induce apoptosis in cocultured T cells through gp120, Fas ligand, and the production of a soluble proapoptotic factor (22, 36). Even though the 43HIV cells were infected for only 2 wk, we performed annexin V staining to ensure that apoptosis of the cocultured T cells didn’t account for the lack of a T cell response. There was no difference in annexin V staining in the T cells cocultured with 43HIV or 43HIV cells transfected with NF-YA compared with T cells cultured with the uninfected cells (data not shown). These findings are in line with our previous studies, which demonstrated that HLA-DR-transfected 43HIV cells that expressed surface HLA-DR were still incapable of inducing an Ag-specific T cell response (25). Furthermore, in colocalization experiments, we demonstrated a diminished capacity to form HLA-DR-Ag complexes (25). The HLA-DR molecules assemble in the endocytoplasmic reticulum associated with Ii, a nonpolymorphic class II gene product that is coordinately expressed with HLA-DR and targets the molecule to either the late endosome or lysosome (55). Decreased production of Ii in the 43HIV cells may explain the inability of the cells to induce an Ag-specific T cell response in our system. We performed PCR for Ii production in 43HIV cells and in the HLA-DR+ and HLA-DR- HIV-1BaL-infected monocytes to determine whether HIV-1 infection also blocked Ii mRNA production.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 3. Transfection of NF-YA-binding protein. The 43HIV cells were transfected with NF-YA cDNA using DEAE-dextran and were then stained with FITC-labeled anti-HLA-DR mAbs. The cells were analyzed by flow cytometry, gating on the live cells. The shaded areas represent staining with the isotype control Abs. The percentage of cells stained with anti-HLA-DR Abs is indicated in the upper right corner. This is representative of an experiment repeated five times.

 


View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 4. The NF-YA-transfected 43HIV cells fail to present Ag to TT-specific T cells. HLA-DR2+ TT-specific, monocyte-depleted T cells were incubated with TT (40 µg/ml) (T+TT), 43 (T+43), 43 plus TT (T+TT+43), 43HIV plus TT (T+TT+43HIV), and NF-YA-transfected 43HIV cells plus TT (T+TT+43HIV+T). The cells were maintained in CM at 37°C for 5 days, and 1 µCi [3H]thymidine was added to the cultures during the last 16 h. The y-axis represents incorporated thymidine. These data represent experiments that were repeated three times.

 


View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 5. Expression of CD80 and CD86 on 43HIV cells. The 43 cells and 43HIV cells transfected with NF-YA were stained with FITC-labeled anti-CD80 and CD86 mAbs and examined by flow cytometry with gating on live cells. The shaded areas represent staining with isotype control Abs, and the percentage of cells stained with FITC-labeled anti-CD80 and CD86 Abs is indicated in the upper right corner. This is representative of an experiment repeated three times.

 
Expression of Ii, HLA-DM-{alpha}, and HLA-DM-{beta} in 43HIV and 63HIV

We extracted RNA from 43 and 43HIV cells and from the HLA-DR+ and HLA-DR- HIV-1BaL-infected monocytes to amplify Ii-specific base pair fragments (410 bp) (Fig. 6Go) by PCR. Bands (410 bp) corresponding to Ii were detected in 43 and 43HIV as well as in the HIVBaL HLA-DR+- and HLA-DR--infected monocytes (Fig. 6Go). Other HLA gene products (HLA-DM-{alpha} and HLA-DM-{beta}) are also coordinately expressed with Ii and are essential in Ag processing (55). HLA-DM-{alpha} and HLA-DM-{beta} further cleave antigenic peptides in subcellular processing compartments, allowing for HLA-DR binding permitting Ag recognition by T cells (56). In the processing compartments, Ii is degraded into several peptides, including CLIP and leupeptin-induced protein (LIP). CLIP binds to the Ag-binding groove of the class II molecules and is removed first before endocytically generated antigenic peptides can bind. The removal of CLIP is catalyzed by HLA-DM. LIP is a 14-kDa NH2-terminal fragment of the Ii that accumulates in the presence of the protease inhibitor leupeptin (37). Impaired production of HLA-DM-{alpha} and HLA-DM-{beta} could possibly explain the failure to induce T cell proliferation in response to TT in the 43HIV cells. We determined by PCR whether HLA-DM-{alpha} and HLA-DM-{beta} were present in 43, 43HIV, and in HLA-DR+ and HLA-DR- HIVBaL-infected monocytes. Similar to the results obtained with Ii, there was no difference in expression of either HLA-DM-{alpha} (341 bp) or HLA-DM-{beta} (321 bp) in 43, 43HIV, or in the HLA-DR+ and HLA-DR- HIV-1BaL-infected monocytes (Fig. 5Go). However, the Ii breakdown products CLIP and LIP were present in the uninfected 43 cells, but absent in the 43HIV cells (Fig. 7Go, A and B). The PIN.1 mAb identifies not only LIP, but also the {alpha}-chain (molecular mass 30 kDa) and {beta}-chain (molecular mass 28 kDa) of HLA-DR, which are present in both the 43 and 43HIV cells. The presence of Ii and HLA-DM-{alpha} and HLA-DM-{beta} in the 43HIV cells in the absence of Ii breakdown products suggested a sorting defect.



View larger version (111K):
[in this window]
[in a new window]
  		FIGURE 6. PCR for Ii, HLA-DM-{alpha}, and HLA-DM-{beta}. RNA was isolated from the 43, 43HIV, and HIV-1BaL HLA-DR+ and HLA-DR- monocytes. The RNA was reverse transcribed, probed with HLA-DM-{alpha}, HLA-DM-{beta}, Ii, and actin-specific probes, and then run on a 5% agarose gel. This is representative of an experiment repeated five times.

 


View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 7. Ii breakdown products in the 43 and 43HIV cells. A, The presence of CLIP in the 43 and the 43HIV cells was demonstrated by intracytoplasmic staining with FITC-labeled anti-CLIP mAbs with gating on live cells. The shaded areas represent staining with isotype control Abs. The percentage of cells stained with CLIP is indicated in the upper right corner. This is representative of an experiment repeated three times. B, Presence of LIP in the 43 and 43HIV cells. Lysates from the 43 and 43HIV cells were run on a 10% SDS-PAGE, transferred onto a nitrocellulose membrane, blotted with the anti-PIN.1 mAb, and then developed. This is representative of an experiment repeated three times.

 
Impaired class II sorting in 43HIV cells

To follow the sorting of HLA-DR into subcellular trafficking compartments, we permeabilized uninfected 43 cells along with the NF-YA-transfected 43HIV cells and stained with FITC-labeled anti-HLA-DR Abs and Texas Red-labeled anti-early endosome (cathepsin D), anti-late endosome (M6PR), anti-lysosome (CD63), and anti-acidic compartment Abs (DAMP). In the uninfected 43 cells, HLA-DR was present (yellow staining) in the late endosomes, acidic compartments, and lysosomes (Fig. 8Go). However, in the NF-YA-transfected 43HIV cells, HLA-DR did not localize into any subcellular compartment (Fig. 8Go). It is possible that there was competition between HIV-1 peptides and normal endosomal and lysosomal targeting that may have prevented HLA-DR sorting. To address this possibility, we introduced env, gag, pol, and nef proteins into uninfected 43 cells using vaccinia virus that contained vectors for different HIV-1 proteins, and then attempted to colocalize HLA-DR in the early and late endosomes, lysosomes, and acidic compartments.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 8. Colocalization of HLA-DR in different trafficking compartments in 43 and 43HIV cells. The NF-YA-transfected HIV-1-infected and uninfected 43 cells were stained intracytoplasmically with FITC-labeled anti-HLA-DR and Texas Red-labeled anti-cathepsin D (early events), anti-DAMP (acidic compartments), anti-M6PR (late endosomes), and anti-CD63 (lysosomes) Abs. The cells were then examined by laser confocal microscopy. Yellow staining (red plus green equals yellow) represents colocalization. Two observers routinely examined 10 separate fields. This is representative of an experiment repeated five times.

 
Effect of HIV-1 proteins on class II sorting in 43HIV cells

To ensure that there were comparable amounts of the env, gag, pol, and nef proteins in the 43 cells before performing the colocalization experiments, we stained the cells intracytoplasmically with FITC-labeled human polyclonal anti-HIV-1 Ab (35). Using an empty vaccinia virus vector as a negative control, peak channel shifts corresponding to the presence of intracytoplasmic env, gag, pol, and nef proteins were detected to a comparable degree in the 43 cells after staining (Fig. 9Go). We then repeated the colocalization studies with FITC-labeled anti-HLA-DR Abs and the Texas Red-labeled anti-cathepsin D, anti-M6PR, anti-lysosome, and anti-DAMP Abs. HLA-DR localized (yellow staining) in the late endosomes, lysosomes, and acidic compartments in the 43 cells infected with the empty vaccinia virus (Fig. 10Go). HLA-DR also localized in the same compartments in the 43 and 63 cells that were infected with vaccinia virus containing the pol, gag, and nef proteins (Fig. 8Go). However, in the 43 cells infected with vaccinia virus that contained the env proteins, HLA-DR did not localize in any of the trafficking compartments (Fig. 8Go).



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 9. Presence of HIV-1 proteins in vaccinia virus-infected 43 cells. Vaccinia virus containing HIV-1 pol, gag, nef, and env was cultured with uninfected 43 and 63 cells at a virus to cell ratio of 108:1. The presence of different HIV-1 proteins in the cells was determined by intracytoplasmic staining with polyclonal human anti-HIV-1 Abs, followed by flow cytometry with gating on live cells. The shaded areas represent staining with control isotype Abs. The percentage of cells stained with the anti-HIV-1 Abs is indicated in the upper right corner. This is representative of an experiment repeated three times.

 


View larger version (40K):
[in this window]
[in a new window]
  		FIGURE 10. Colocalization of HLA-DR in subcellular compartments. The 43 cells containing an empty vector and the pol, gag, nef, and env HIV-1 proteins (vaccinia virus infected) were stained intracytoplasmically with Texas Red-labeled anti-cathepsin D (early endosomes), anti-DAMP (acidic compartments), anti-M6PR (late endosomes), anti-CD63 (lysosomes) Abs, and FITC-labeled anti-DR Abs. The cells were examined by laser confocal microscopy. Yellow staining (red plus green equals yellow) represents colocalization. Two observers routinely examined 10 separate fields. This is representative of an experiment repeated five times.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have extended our previous studies investigating the effect of HIV-1 infection on class II expression in monocytic cells (22, 25). Using a human macrophage hybridoma model system, we demonstrated that HLA-DR expression was lost 2 wk after HIV-1 infection and could be restored by transfecting HLA-DR genes driven by a nonphysiological CMV promoter (25). The loss of HLA-DR expression in monocytic cell lines and primary monocytes has been variably reported by different investigators, with the percentage of monocytes infected with HIV-1 being between 30% and 70% (19, 20, 22, 25). In the present study, we observed the loss of HLA-DR in 30% of primary monocytes infected with HIV-1BaL (Table IGo). These findings may relate to either varying numbers of infected cells in monocytic preparations or a different effect of HIV-1 infection on HLA-DR expression in monocyte subpopulations. Different subpopulations of monocytes have been described in the peripheral blood of healthy blood donors (57). In one report, the presence of a subtype resembling tissue macrophages expressing CD14+CD16++ was found in the peripheral blood (58, 59). The CD14+CD16++ monocytic population has been reported to be increased in patients with autoimmune diseases, AIDS, and AIDS dementia (60, 61). The human macrophage hybridomas were derived from peripheral blood monocytes and represent clonal expansions of different subpopulations of macrophages (21). The 43 cells express CD14+CD16++ (21). It is possible that selection basis may have occurred during the generation of these cell lines, and our findings of lost HLA-DR expression may represent events occurring in a selected subpopulation of macrophages.

As mentioned above, the loss of HLA-DR expression in the human macrophage hybridomas after HIV-1 infection could be overcome by transfecting HLA-DR-{alpha} and HLA-DR-{beta} genes driven by a nonphysiologic CMV promoter, suggesting an effect on regulatory DNA-binding proteins (25). HLA-DR and other class II genes are regulated by a series of proteins (X and Y box proteins) that bind to conserved elements of DNA (W/S/Z, X-1, X-2, and Y boxes) and CIITA, a non-DNA-binding protein that is an important transcription factor (60). Although RFX-5-, hX-2BP-, NF-YA-, and NF-YB-binding proteins are ubiquitously expressed, CIITA expression is restricted to class II-positive cells (63, 64). The identification of key class II regulatory factors has come from studies of B cell lines derived from patients with BLS, an immunodeficiency characterized by absent HLA class II expression (63, 64).

Four different types of defects have been described in BLS patients based on these studies. Class II deficiency is classified into four categories, A, B, C, and D, depending on the presence or absence of different X box DNA-binding proteins and CIITA (52, 62, 65, 66). Type A has no X box-binding proteins or CIITA activity; types B, C, and D have CIITA activity, but different defects in the X box-binding proteins. The 43HIV cells and HIV-1BaL-infected monocytes that lost HLA-DR expression had no W/Z/S, X-1, X-2, and Y box-binding activity, but had mRNA for CIITA (Fig. 1Go), resembling types B, C, and D class II deficiency. However, mRNA for RFX-5 and hX-2BP was present in these cells. The only defect noted was a loss of the NF-YA DNA-binding protein (Fig. 2Go) that was clearly important for HLA-DR in the human macrophage hybridomas because surface expression could be restored after transfection (Fig. 3Go).

The Y box proteins are necessary for class II expression and are comprised of two protein chains, NF-YA and NF-YB, which are highly homologous to the HAP2 and HAP3 transcription factors of Saccharomyces cerevisiae (67, 68, 69, 70, 71). The loss of the NF-YA DNA-binding protein as it relates to HLA-DR expression appears to be unique to our system. Others have reported that absent NF-YA increased HLA-DR expression and increased the susceptibility to rheumatoid arthritis (72, 73). Interestingly, the NF-YA protein binds to the long terminal repeat of HIV-1 and human T cell leukemia virus-1, can activate transcription of viral gene products, and is related to the Rous sarcoma virus enhancer factor I (74, 75, 76).

The regulation of class II expression in APC, including HLA-DR, HLA-DQ, HLA-DP, HLA-DM-{alpha}, HLA-DM-{beta}, and Ii, probably involves an intricate regulatory unit consisting of multiple protein complexes (54). The high synergy in DNA-protein complex formation between RFX-5 and hX-2BP suggests that these proteins interact first to form the class II transcription complex (77, 78). The NF-YA and NF-YB proteins stabilize the interaction between RFX-5 and hX-2BP, which then recruits and binds CIITA, which activates transcription of class II gene products through its acidic activation domain (54). The data in Fig. 1Goa demonstrate that there was no binding of nuclear extracts from the 43HIV cells and the HIV-1BaL-infected monocytes that lost HLA-DR expression to X box, Y box, and the W/S/Z box. The loss of binding of the X box proteins in the gel-shift assay (Fig. 1Goa) may be due to the lack of stability of the RFX-hX2-BP complex due to the absence of NF-YA. Because RFX is also important for W/Z/S binding, the same might hold true for the absence of binding to the W/Z/S box.

One of the interesting features of our system is that there is selective loss of mRNA for HLA-DR, while mRNA for HLA-DM-{alpha} and HLA-DM-{beta} and Ii are transcribed. Although HLA-DR, HLA-DM-{alpha}, HLA-DM-{beta}, and Ii are reported to be transcribed coordinately by some investigators (79), more recent studies have shown that HLA-DR and Ii genes are not always coordinately transcribed (80, 81, 82). The HLA-DR and Ii promoters differ in spacing between the X and Y boxes (83, 84), and mutational analysis of HLA-DR and Ii promoters has demonstrated differences in the contribution of W/Z/S box binding (52). Subtle differences in promoter occupancy have also been noted between HLA-DR and Ii (81). Because differences in the stability of the class II transcription complex have been observed (85, 86, 87), it is conceivable that the lack of NF-YA-binding protein in vivo may alter the stability of this complex, accounting for the selective loss of HLA-DR transcription.

The loss of class II mRNA expression in monocytic cells after HIV-1 infection, associated with defects in transcription factors, has also been reported by other investigators. Kanazawa et al. (26) have demonstrated that the Tat protein competed with CIITA for binding to P-TEFb, an activation factor that is required for class II transcription, and blocked the expression of class II genes in THP-1 cells. Tat inhibition of the binding of CIITA to P-TEFb could be occurring to impair class II mRNA transcription. However, because there was selective loss of HLA-DR in the 43HIV cells and in the HIV-1BaL-infected monocytes, it is uncertain how much of a role this may be playing in our system. It is possible that HIV-1 infection may have multiple effects on the regulation of class II expression in different subpopulations of monocytic cells.

We have previously reported that there was defective APC function in HIV-1-infected human macrophage hybridomas that expressed HLA-DR after transfection with full-length HLA-DR cDNA driven by a CMV promoter (25). Furthermore, in these cells there was no Ag-class II complex formation, implying dysregulation of intracellular sorting (25). Similarly, in this study, the 43HIV cells were incapable of inducing a T cell proliferative response after HLA-DR expression was restored following transfection with NF-YA (Fig. 4Go), even though there was no change in CD80 and CD86 expression (Fig. 5Go). Despite the fact we detected mRNA for Ii in the 43HIV cells (Fig. 6Go), there were no Ii breakdown products (CLIP and LIP) (Fig. 7Go) and HLA-DR failed to localize in either the late endosomes, lysosomes, or acidic compartments (Fig. 8Go). Infection of the 43 cells with vaccinia virus expressing different HIV-1 proteins demonstrated that only the env protein prevented localization of HLA-DR in either the late endosomes or lysosomes (Fig. 10Go). In human cells, two forms of Ii target HLA-DR molecules to endosomal processing compartments, a 33-kDa isoform and a 35-kDa isoform (87). The 33-kDa Ii isotype constitutes 80% of the Ii pool and traffics to the Ag-processing compartments via the cell surface, while the 35-kDa Ii targets endosomal compartments by a strictly intracellular route (85). Similar to the Ii 33-kDa isoform, the env protein is also synthesized in the endoplasmic reticulum, transported to the cell surface, and then endocytosed, where it enters into the processing compartments (88, 89, 90). The envelope protein contains motifs for tyrosine-based sorting signals that are present in many endocytic receptors.

It is not entirely clear how the HIV-1 env protein could inhibit Ii targeting in our system. The leucine motif present in the cytoplasmic domain of both the 33-kDa and 35-kDa isoforms targets the Ag-processing compartments (91). Proteins like the 33-kDa isoform of Ii and HIV-1 env protein that are internalized from the cell surface before delivery into the late endosomes or lysosomes cluster into regions on the cell membrane that are underlain with the coat protein clathrin (92, 93, 94). After internalization, an adapter complex is formed (95). One well-characterized adapter complex, AP-2, mediates the association of clathrin with the plasma membrane (95). The AP-2 complex consists of four protein subunits 2~100-kDa large chains ({alpha}-adapter and either {beta}-2 or {beta}-1 adaptor), a 50-kDa medium chain, µ2 and a 17-kDa small {varsigma}2 protein (96). Early experiments indicate that the cytosolic domains of internalized proteins could be bound with low affinity by the AP-2 adapter complex (97, 98). Evidence from several laboratories has established that the AP-2 adapter complex recognizes both tyrosine-based and di-leucine-based sorting signals (99, 100, 101). Ohno et al. (103) have demonstrated that the HIV-1 env protein can bind to members of the AP-2 adapter complex, and overexpression of the env protein saturates intracellular sorting into different subcellular compartments (96). Competition between env protein and Ii may inhibit the localization of HLA-DR to the late endosomes, lysosomes, and acidic compartments in the 43HIV cells and in the 43 cells infected with vaccinia virus expressing the env protein.

In conclusion, we have demonstrated that the loss of HLA-DR expression after HIV-1 infection is associated with the loss of the NF-YA Y box-binding protein in 43HIV cells and primary HIV-1BaL-infected monocytes that lost HLA-DR expression. Despite the fact that the block in HLA-DR production could be overcome by transfection with NF-YA driven by a CMV promoter, the cells were still incapable of inducing Ag-specific T cell proliferation. Even though there was Ii mRNA in the HIV-1-infected human macrophage hybridomas, HLA-DR failed to localize in the late endosomes, lysosomes, or acidic compartments. The HIV-1 env protein appears to interfere with the trafficking of HLA-DR into late endosomes, lysosomes, and acidic compartments in the HIV-1-infected human macrophage hybridomas. HIV-1 infection has multiple effects on Ag processing in monocytic cells, which may contribute to the immune defects seen in HIV-1-infected patients.


   Footnotes
 
1 This work was supported by National Institutes of Health Grants CAR-29-256990, PO-1-AI-44236, and AI-45343 and the Irma T. Hirschl Career Development Trust (all to K.S.). Confocal laser-scanning microscopy was performed at the Mount Sinai School of Medicine Confocal Laser Scanning Microscopy core facility, supported with funding from National Institutes of Health Shared Instrumentation Grant 1S10RR09145-01 and National Science Foundation Major Research Instrumentation Grant DB1-9724504. Back

2 Address correspondence and reprint requests to Dr. Kirk Sperber, Division of Clinical Immunology, Mount Sinai Medical Center, Box 1089, 1425 Madison Avenue, New York, NY 10029. E-mail address: kirk.sperber{at}mssm.edu Back

3 Abbreviations used in this paper: CIITA, MHC class II transactivator; BLS, bare lymphocyte syndrome; CLIP, class II-associated Ii peptide; CM, complete medium; DAMP, 3-(2,4-dinitroanilino)-3'-N-methyldipropylamine; Ii, invariant chain; LIP, leupeptin-induced protein; TT, tetanus toxoid. Back

Received for publication August 31, 2000. Accepted for publication June 6, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Unanue, E.. 1989. Macrophage, antigen-presenting cells, and the phenomena of antigen handling and presentation. Fundamental Immunology 2nd Ed.567.-599. Raven Press, New York.
  2. Unanue, E.. 1984. Antigen-presenting function of the macrophage. Annu. Rev. Immunol. 3:973.
  3. Tishon, A., P. Burrows, C. Evans, M. B. A. Oldstone. 1993. Virus-induced immunosuppression. Virology 195:397.[Medline]
  4. Meltzer, M. S., D. R. Skilman, D. L. Hoover, B. D. Hanson, J. A. Turpin, C. D. Kalter, H. E. Gendelman. 1990. Macrophages and the human immunodeficiency virus. Immunol. Today 11:217.[Medline]
  5. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phillips, L. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al 1987. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulatory factor 1-treated monocytes. J. Exp. Med. 167:1428.[Abstract/Free Full Text]
  6. Gartner, S., P. Markovits, D. M. Markovits, M. Kaplan, R. Gallo, M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215.[Abstract/Free Full Text]
  7. Bender, B. S., B. L. Davidson, R. Kline, C. Brown, T. C. Quinn. 1988. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev. Infect. Dis. 10:1142.[Medline]
  8. McElrath, M. J., J. E. Pruett, Z. A. Cohn. 1989. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type I infections. Proc. Natl. Acad. Sci. USA 86:675.[Abstract/Free Full Text]
  9. Poli, G., B. Bottazzi, R. Acero, L. Bersani, V. Rossi, M. Introna, A. Lazzarin, M. Galli, A. Mantovani. 1985. Monocyte function in intravenous drug abusers with lymphadenopathy syndrome: selective impairment of chemotaxis. Clin. Exp. Immunol. 62:136.[Medline]
  10. Smith, P. D., K. Ohura, H. Masur, H. C. Lane, A. S. Fauci, S. M. Wahl. 1984. Monocyte-Macrophage function in the acquired immunodeficiency syndrome: defective chemotaxis. J. Clin. Invest. 74:2121.
  11. Wahl, S. M., J. B. Allen, S. Gartner, J. M. Orenstein, M. Popovic, D. E. Chenoweth, L. O. Arthur, W. L. Farrar, L. M. Wahl. 1989. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J. Immunol. 142:3553.[Abstract]
  12. Roux-Lombard, P., C. Modoux, A. Cruchaund, J. M. Dayer. 1989. Purified blood monocytes from HIV-1 infected patients produce high levels of TNF-{alpha} and IL-1. Clin. Immunol. Immunopathol. 50:374.[Medline]
  13. McCartney-Francis, N., D. E. Mitzel, J. B. Allen, L. M. Wahl, P. D. Smith, T. M. Folks, S. M. Wahl. 1987. Human immunodeficiency virus (HIV) induces gene expression for interleukin-2 (IL-2) receptors on human monocytes. J. Cell. Biochem. 11:56.
  14. Rich, E. A., Z. Tooshi, H. Fujiwara, R. Hanigosky, M. M. Lederman, J. J. Ellner. 1988. Defective accessory function of monocytes in human immunodeficiency virus-related disease syndrome. J. Lab. Clin. Med. 112:174.[Medline]
  15. Prince, H. E., D. J. Moody, B. I. Shubin, J. L. Fahey. 1985. Defective monocyte function in acquired immune deficiency syndrome (AIDS): evidence from a monocyte-dependent T-cell proliferative system. J. Clin. Immunol. 5:21.[Medline]
  16. Petit, A. J., M. Termette, F. G. Terpstra, R. E. de Goede, R. A. van Lier, F. Miedema. 1988. Decreased accessory cell function by human monocyte cells after infection with HIV. J. Immunol. 140:1485.[Abstract]
  17. Ennen, J., I. Seipp, S. G. Norley, R. Kurth. 1990. Decreased accessory cell function of macrophages after infection with human immunodeficiency virus type 1 in vitro. Eur. J. Immunol. 20:2451.[Medline]
  18. Petit, A. J. C., F. G. Terpstra, F. Miedema. 1989. Human immunodeficiency virus infection down-regulates HLA class II expression and induces differentiation in promonocytic U937 cells. J. Clin. Invest. 79:1883.
  19. Mann, D. L., S. Gartner, F. LeSane, W. A. Blattner, M. Popovic. 1990. Cell surface antigens and function of monocytes and a monocyte-like cell line before and after infection with HIV. Clin. Immunol. Immunopathol. 54:174.[Medline]
  20. Meyaard, L., H. Schuitemaker, F. Miedema. 1993. T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function. Immunol. Today 14:123.
  21. Sperber, K., A. Pizzimenti, V. Najfeld, L. Mayer. 1990. Identification of subpopulations of human macrophages through the generation of human macrophage hybridomas. J. Immunol. Methods 129:31.[Medline]
  22. Sperber, K., G. Hamrang, M. J. Louie, T. Kalb, R. Banerjee, H. S. Choi, F. Paronetto, L. Mayer. 1993. Progressive impairment of monocytic function in HIV-1 infected human macrophage hybridomas. AIDS Res. Hum. Retroviruses 9:657.[Medline]
  23. Yoo, J., H. Chen, T. Kraus, D. Hirsch, S. Poylak, I. George, K. Sperber. 1996. Altered cytokine and accessory cell function after HIV-1 infection. J. Immunol. 156:1313.
  24. Sperber, K., A. Shaked, D. N. Posnett, S. Z. Hirschman, J. G. Bekesi, L. Mayer. 1990. Surface expression of CD4 does not predict susceptibility to infection with HIV-1 in human monocyte hybridomas. J. Clin. Lab. Immunol. 31:151.[Medline]
  25. Polyak, S., H. Chen, D. Hirsch, I. George, R. Hirschberg, K. Sperber. 1997. Impaired class II expression and impaired antigen uptake in monocytic cells after HIV-1 infection. J. Immunol. 159:2177.[Abstract/Free Full Text]
  26. Kanazawa, S., T. Okamoto, B. M. Perterlin. 2000. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61.[Medline]
  27. Glimcher, L. H., C. J. Cara. 1992. Sequences and factors: a guide to MHC class II transcription. Annu. Rev. Immunol. 10:13.[Medline]
  28. Kobr, M., W. Reith, C. H. Herrero-Sanchez, B. Mach. 1990. Two DNA-binding proteins discriminate between the promotors of different members of the major histocompatibility complex class II multigene family. Mol. Cell. Biol. 10:965.[Abstract/Free Full Text]
  29. Liou, H. C., M. R. Boothy, P. W. Finn, R. Davidson, N. Nabavi, N. J. Zelynik-Le, J. P. Y. Ting. 1990. A new member of the leucine zipper class of proteins that binds to the HLA-DRa promoter. Science 247:1581.[Abstract/Free Full Text]
  30. Reith, W., E. Borros, S. Soloter, M. Kobr. 1989. Cloning of the major histocompatibility complex class II promoter binding protein affected in a hereditary defect in class II gene regulation. Proc. Natl. Acad. Sci. USA 86:4200.[Abstract/Free Full Text]
  31. Ting, J. P., A. S. Baldwin. 1993. Regulation of MHC gene expression. Curr. Opin. Immunol. 5:8.[Medline]
  32. Plevy, S. E., J. H. Gemberling, S. Hsu, A. J. Dorner, S. T. Smale. 1997. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promotors: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17:4572.[Abstract]
  33. Dingham, J. D., R. M. Lebowitz, R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475.[Abstract/Free Full Text]
  34. Sperber, K., T. Kalb, V. Stecher, L. Mayer. 1993. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res. Hum. Retroviruses 9:91.[Medline]
  35. Sussman, D. J., G. Milman. 1984. Short-term, high-efficiency expression of transfected DNA. Mol. Cell. Biol. 4:1641.[Abstract/Free Full Text]
  36. Chen, H., Y. K. Yip, I. George, M. Tyorkin, E. Salik, K. Sperber. 1998. Chronically HIV-1 infected monocytic cells induce apoptosis in co-cultured T cells. J. Immunol. 161:4257.[Abstract/Free Full Text]
  37. Denzin, L. K., C. Hammond, P. Cresswell. 1996. HLA-DM interacts with intermediates in HLA-DR maturation and a role of HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184:2153.[Abstract/Free Full Text]
  38. Takahashi, H., S. D. Putney, R. Houghten, B. Moss, R. N. Germain, J. A. Berzosky. 1989. A single amino acid interchange yields CTL specificity for gp160. Science 246:118.[Abstract/Free Full Text]
  39. Chang, C. H., J. D. Fontes, B. M. Peterlin, R. A. Flavell. 1994. Class II trans-activator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180:1367.[Abstract/Free Full Text]
  40. Kara, C. J., L. M. Glimcher. 1991. In vivo footprinting of MHC class II genes: bare promoters in the bare lymphocyte syndrome. Science 252:709.[Abstract/Free Full Text]
  41. Steimle, V., L. A. Otten, M. Zufferey, B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (bare lymphocyte syndrome). Cell 75:135.[Medline]
  42. Chang, C., S. Guerder, S. Hong, W. Van Ewijk, R. Flavel. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4:167.[Medline]
  43. Griscelli, C., B. Lisowska-Grospierre, B. Mach. 1989. Combined immunodeficiency with defective expression in MHC class II genes. Immunodefic. Rev. 1:135.[Medline]
  44. Chang, C. H., R. A. Flavell. 1995. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. 181:756.
  45. Steimle, D., B. Durand, B. Emmanuele, M. Zufferey, M. R. Hadam, B. Mach, W. A. Reith. 1995. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021.[Abstract/Free Full Text]
  46. Durand, B., M. Kobr, W. Reith, B. Mach. 1994. Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX. Mol. Cell. Biol. 14:6839.[Abstract/Free Full Text]
  47. Emery, P., B. Durand, B. Mach, W. Reith. 1996. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res. 24:803.[Abstract/Free Full Text]
  48. Sloan, J. H., S. L. Hasegawa, J. M. Boss. 1992. Single base pair mutations within HLA-DRA promoter separate the functions of X1 and X2 boxes. J. Immunol. 148:2591.[Abstract]
  49. Ronchi, A., M. Bellorini, N. Mongelli, R. Montovani. 1995. CCAAT-box binding protein NF-Y (CBF, CP1) recognizes the minor groove and distorts DNA. Nucleic Acids Res. 23:4565.[Abstract/Free Full Text]
  50. Herrero-Sanchez, C., W. Reith, P. Silacci, B. Mach. 1992. The DNA-binding effect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to X boxes of class II promoters. Mol. Cell. Biol. 12:4076.[Abstract/Free Full Text]
  51. Riley, J. L., S. D. Westerheide, J. A. Price, J. A. Brown, J. M. Boss. 1995. Activation of class II MHC genes requires both the X box region and class II transactivation (CIITA). Immunity 2:533.[Medline]
  52. Jabrane-Ferrat, N., J. D. Fontes, J. M. Boss, B. M. Peterlin. 1996. Complex architecture of major histocompatibility complex class II promoters: re-interated motifs and conserved protein-protein interactions. Mol. Cell. Biol. 16:4683.[Abstract]
  53. Reith, W., S. Satola, C. Herrero-Sanchez, I. Armaldi, B. Lisowsaka-Grospierre, C. Griscelli, M. R. Hadam, B. Mach. 1988. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RX-X. Cell 53:897.[Medline]
  54. Boss, J. M.. 1997. Regulation of transcription of MHC class II genes. Curr. Opin. Immunol. 9:107.[Medline]
  55. Cresswell, P.. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259.[Medline]
  56. Denzin, L. K., P. Cresswell. 1995. HLA-DM induces CLIP dissociation from MHC class II {beta} dimers and facilitates peptide loading. Cell 82:155.[Medline]
  57. Ziegler-Heitbrock, H. W.. 1996. Heterogeneity of human blood monocytes: the CD14+ CD162+ subpopulation. Immunol. Today 17:424.[Medline]
  58. Zieglar-Heitbrock, H. W., G. Fingerele, M. Strohl, W. Schraut, F. Steller, C. Scht, B. Passalick, A. Pforte. 1993. The novel subset of CD14+CD162+ blood monocytes exhibit features of tissue macrophages. Eur. J. Immunol. 23:2053.[Medline]
  59. Fingerele-Rowson, G., M. Angstwurm, R. Andressen, H. W. Ziegler- Heitbrock. 1998. Selective depletion of CD14+CD16+ monocytes by glucosteroid therapy. Clin. Exp. Immunol. 112:501.[Medline]
  60. Thieblemont, N., L. Weiss, N. M. Sedeghi, H. M. Estcourt, N. Haeffner-Cavaillon. 1995. CD14lowCD16high, a cytokine producing monocyte subset expands during the human immunodeficiency virus infection. Eur. J. Immunol. 25:3418.[Medline]
  61. Pulliam, L., R. Gascon, M. Stubblebine, D. McGwire, M. S. McGrath. 1997. Unique monocyte subset in patients with AIDS dementia. Lancet 349:692.[Medline]
  62. Reith, W., V. Steimle, B. Mach. 1995. Molecular defects in the bare lymphocyte syndrome and regulation of MHC class II genes. Immunol. Today 16:539.[Medline]
  63. Chang, C. H., J. D. Fontes, M. Peterlin, R. A. Flavell. 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex genes. J. Exp. Med. 180:1367.
  64. Steimle, V., C. A. Siegrist, A. Mottet, B. Lisowska-Grospierre, B. Mach. 1994. Regulation of MHC class II expression by interferon-{gamma} mediated by the transactivator gene CIITA. Science 265:106.[Abstract/Free Full Text]
  65. Benichou, B., J. L. Strominger. 1991. Class II negative patient and mutant B-cell lines represent at least 3, and probably 4 distinct genetic defects defined by complementation analysis. Proc. Natl. Acad. Sci. USA 88:4285.[Abstract/Free Full Text]
  66. Seidl, C., C. Saraiya, Z. Osterweil, Y. P. Fu, J. S. Lee. 1992. Genetic complexity of regulatory molecules defective for HLA class II expression. J. Immunol. 148:1576.[Abstract]
  67. Sinha, S., S. N. Maity, J. Lu, B. De Crombrugghe. 1995. Recombinant rat CCBF-C, the third subunit of CBF/NFY, allows formation of a protein-DNA complex with CBF-A and CBF-B and with yeast HAP2 and HAP3. Proc. Natl. Acad. Sci. USA 92:1624.[Abstract/Free Full Text]
  68. Didier, P. K., J. Schiffenbaurer, S. L. Woulfe, M. Zucheis. 1988. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex II Y box. Proc. Natl. Acad. Sci. USA 85:7322.[Abstract/Free Full Text]
  69. Van Huijduynen, R. H., X. Y. Li, D. Bloch, H. Mattes, C. Benoiste, D. Mathis. 1990. Co-evolution from yeast to mouse: cDNA cloning of two NY-F CCP-1/CBF subunits. EMBO J. 9:3119.[Medline]
  70. Tafuri, S. R., A. P. Wolfe. 1990. Xenopus Y-box transcription factors: molecular cloning, functional analysis and development regulation. Proc. Natl. Acad. Sci. USA 87:9028.[Abstract/Free Full Text]
  71. Reith, W., C. A. Siegrist, B. Durand, E. Barras, B. Mach. 1991. Function of major histocompatibility complex class II promoters requires cooperative binding between RFX and NF-Y. Proc. Natl. Acad. Sci. USA 91:554.[Abstract/Free Full Text]
  72. Singal, D. P., M. Ye, W. W. Buchanan, X. Qiu. 1996. Y-box binding trans-regulatory nuclear proteins and susceptibility to rheumatoid arthritis. Clin. Exp. Arthritis 14:669.
  73. Haas, J. P., A. Kimura, H. Truckenbrodt, J. Suschke, T. Sasazuki, A. Volgger, E. D. Albert. 1995. Early-onset pauciarticular juvenile chronic arthritis is associated with a mutation in the Y-box of the HLA-DQA1 promoter. Tissue Antigens 45:317.[Medline]
  74. Sawaya, B. E., K. Knalil, S. Amini. 1998. Transcription of the human immunodeficiency virus type 1 (HIV-1) promoter in central nervous systems cells: effects of YB-1 on expression of the HIV-1 long terminal repeat. J. Gen. Virol. 79:239.[Abstract]
  75. Kashanchi, F., J. F. Duval, J. Dittmer, A. Mireskandari, R. L. Reid, S. D. Gitlin, J. N. Brady. 1994. Involvement of transcription factor YB-1 in human T-cell lymphotropic virus type 1 basal gene expression. J. Virol. 68:561.[Abstract/Free Full Text]
  76. Faber, M., L. Sealy. 1990. Rous sarcoma enhancer factor I is a ubiquitous CCAAT transcription factor highly related to CBF and NF-Y. J. Biol. Chem. 265:22243.[Abstract/Free Full Text]
  77. Kara, C. J., L. H. Glimcher. 1991. In vivo footprinting of MHC class II genes: bare promoters in the bare lymphocyte syndrome. Science 252:709.
  78. Moreno, C. S., P. Emery, J. E. West, B. Durand, W. Reith, B. Mach, J. L. Boss. 1995. Purified X2-BP cooperatively binds the class II MHC X box region in the presence of purified RFX, the X box factor deficient in the bare lymphocyte syndrome. J. Immunol. 155:4313.[Abstract]
  79. Kovats, S., S. Drover, W. Marshall, D. Freed, P. Whitely, G. T. Nepom, J. S. Blum. 1994. Coordinate defects in class II expression and antigen presentation in bare lymphocyte syndrome. J. Exp. Med. 179:2017.[Abstract/Free Full Text]
  80. Zhu, L., P. P. Jones. 1990. Transcriptional control of the invariant chain gene involves promoter and enhancer elements common and distinct from major histocompatibility complex class II genes. Mol. Cell. Biol. 10:3908.
  81. Mach, B., V. Steimle, E. Martinez-Soria, W. Reith. 1996. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301.[Medline]
  82. Hauber, I., H. Gulle, H. M. Wolf, M. Maris, H. Eggenbauer, M. M. Eibl. 1995. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell responses indicate a new phenotype. J. Exp. Med. 181:1411.[Abstract/Free Full Text]
  83. Wright, K. L., J. P. Ting. 1992. In vivo footprint analysis of HLA-DRA gene promoter: cell specific interaction at the octomer site and up-regulation of X box binding by interferon-{gamma}. Proc. Natl. Acad. Sci. USA 89:7601.[Abstract/Free Full Text]
  84. Wright, K. L., T. L. Moore, B. J. Vilen, A. M. Brown, J. P.-Y. Ting. 1995. Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Spl and NF-Y. J. Biol. Chem. 270:20978.[Abstract/Free Full Text]
  85. Vilen, B. J., J. P. Cogswell, J. P.-Y. Ting. 1991. Stereospecific alignment for the X and Y elements is required for major histocompatibility complex II DRA promoter function. Mol. Cell. Biol. 11:2406.[Abstract/Free Full Text]
  86. Thanos, D., T. Maiatis. 1995. Virus induction of human IFB{beta} gene expression requires the assembly of an enhanceosome. Cell 83:1091.[Medline]
  87. Douhan III, J., I. Hauber, M. M. Eibl, L. H. Glimcher. 1996. Genetic evidence for a new type major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D {alpha} and {beta} chains. J. Exp. Med. 183:1063.[Abstract/Free Full Text]
  88. Warmerdam, P. A. M., E. O. Long, P. A. Roche. 1996. Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments. J. Cell Biol. 133:281.[Abstract/Free Full Text]
  89. Lotteau, V., L. Teyton, A. Peleraux, T. Nilsson, A. Karlsson, S. L. Schmid, V. Quaranta, P. A. Peterson. 1990. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348:600.[Medline]
  90. Roche, P. A., C. L. Teletski, E. Stang, O. Bakke, E. O. Long. 1993. Cell surface HLA-DR invariant chain complexes are targeted to endosomes by rapid internalization. Proc. Natl. Acad. Sci. USA 90:8581.[Abstract/Free Full Text]
  91. Trowbridge, I. S., J. F. Collawn, C. R. Hopkins. 1993. Signal-dependent membrane trafficking in the endocytic pathway. Annu. Rev. Cell Biol. 9:129.
  92. Pond, L., L. A. Kuhn, L. Teyton, M. P. Schutze, J. A. Trainer, M. R. Jackson, amd P. A. Peterson. 1995. A role for acid residues in di-leucine targeting to the endocytic pathway. J. Biol. Chem. 34:19998.9.
  93. Wang, K., P. A. Peterson, L. Karlsson. 1997. Decreased endosomal delivery of major histocompatibility complex class II-invariant chain complex in dynanin-deficient cells. J. Cell Biol. 272:17055.
  94. Callahan, K. M., J. F. Rowell, M. J. Soloski, C. E. Machamer, R. F. Siliciano. 1993. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes. J. Immunol. 151:2928.[Abstract]
  95. Rowell, J. F., P. E. Stanhope, R. F. Siliciano. 1995. Endocytosis of endogenously synthesized HIV-1 envelope protein. J. Immunol. 155:473.[Abstract]
  96. Kirchhauser, T.. 1993. Coated pits and coated vesicles: sorting it all out. Curr. Opin. Struct. Biol. 2:182.
  97. Marks, M. S., H. Ohno, T. Kirchhuasen, J. S. Bonifacino. 1997. Protein sorting by tyrosine-based signals: adapting to the Ys and wherefore. Trends Cell Biol. 7:125.
  98. Pearse, B. M. F.. 1988. Receptors compete for adapters found in plasma membrane coated pits. EMBO J. 7:3331.[Medline]
  99. Glickman, J. N., E. Conibeau, B. M. F. Pearse. 1989. Specificity of binding of clathrin adaptors to signals on mannose-6-phosphate insulin-like growth factor II receptors. EMBO J. 8:1041.[Medline]
  100. Ohno, H., M. C. Fournier, G. Poy, J. S. Bonifacino. 1996. Structural determinants of interaction of tyrosine-based sorting with adapter medium chains. J. Biol. Chem. 271:29009.[Abstract/Free Full Text]
  101. Boll, W., Z. Songyang, L. Rapoport, L. C. Contley, J. S. Bonifacino, T. Kirchhausen. 1996. Sequence requirements for the recognition of tyrosine-based endocytic signals by clathrin AP-2 complexes. EMBO J. 15:5789.[Medline]
  102. Heilken, R., U. Manning-Kreig, J. F. Zuber, M. Speiss. 1996. In vitro binding clathrin adapters to sorting signals correlate with endocytosis and basolateral sorting. EMBO J. 15:2893.[Medline]
  103. Ohno, H., R. C. Aguilar, M. C. Fournier, S. Hennecke, P. Cosson, J. S. Bonifacino. 1997. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adapter medium chain family. Virology 238:305.[Medline]

Related articles in The JI:

Regulation of class II expression in monocytic cells after HIV-1 infection.
S. Rakoff-Nahoum, H. Chen, T. Kraus, I. George, E. Oei, M. Tyorkin, E. Salik, P. Beuria, and K. Sperber
The JI 2005 175: 8442. [Full Text]  

Retraction: Regulation of Class II Expression in Monocytic Cells after HIV-1 Infection
Seth Rakoff-Nahoum, Houchu Chen, Thomas Kraus, Italas George, Erwin Oei, Max Tyorkin, Erez Salik, Prarthana Beuria, and Kirk Sperber
The JI 2006 177: 6561. [Full Text]  



This article has been cited by other articles:


Home page
 CVIHome page
P. Beuria, H. Chen, M. Timoney, and K. Sperber
Impaired Accessory Cell Function in a Human Dendritic Cell Line after Human Immunodeficiency Virus Infection
Clin. Vaccine Immunol., March 1, 2005; 12(3): 453 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. Oei, T. Kalb, P. Beuria, M. Allez, A. Nakazawa, M. Azuma, M. Timony, Z. Stuart, H. Chen, and K. Sperber
Accessory cell function of airway epithelial cells
Am J Physiol Lung Cell Mol Physiol, August 1, 2004; 287(2): L318 - L331.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Sperber, P. Beuria, N. Singha, I. Gelman, P. Cortes, H. Chen, and T. Kraus
Induction of Apoptosis by HIV-1-Infected Monocytic Cells
J. Immunol., February 1, 2003; 170(3): 1566 - 1578.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
L. Shao and K. Sperber
Impaired Regulation of HLA-DR Expression in Human Immunodeficiency Virus-Infected Monocytes
Clin. Vaccine Immunol., July 1, 2002; 9(4): 739 - 746.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow A retraction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rakoff-Nahoum, S.
Right arrow Articles by Sperber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rakoff-Nahoum, S.
Right arrow Articles by Sperber, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS